Steve Williamson, MRPharmS (IPresc) from Northumbria Healthcare Trust, Newcastle upon Tyne, UK discusses the availability of biosimilars in the UK at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Biosimilars have been used in hematology previously but we are seeing the first introduction of monoclonal antibody biosimilars now. In Mr. Williams’ opinion as a Consultant Pharmacist, clinicians have not been provided with sufficient information about the availability and use of biosimilars, therefore they do not know what to expect once they are made available in the UK. There is an expectation for commissioners to release guidelines regarding the replacement of the current antibodies, and the deadlines for the switch-over of current patients. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates